Related Experiment Video
Updated: Mar 31, 2026

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors
Published on: December 7, 2014
Ruxolitinib reverses systemic vasculitis driven by JAK2 V617F-mutated essential thrombocythemia: a case report
Yutaro Ashida1, Shinji Ota1, Nao Ishidoya1
1Department of Gastroenterology, Hematology, and Clinical Immunology, Hirosaki University Graduate School of Medicine, Hirosaki, Japan.
This study reports a rare case of vasculitis in a patient with Janus Kinase 2 (JAK2) V617F mutation-positive essential thrombocythemia. Ruxolitinib effectively treated the vasculitis, preventing cardiovascular events.
Area of Science:
- Hematology
- Oncology
- Rheumatology
Background:
- Vasculitis is a rare complication of myeloproliferative neoplasms.
- Essential thrombocythemia (ET) is a myeloproliferative neoplasm.
- Reports on treating vasculitis in ET are limited.
Related Concept Videos
The JAK-STAT Signaling Pathway
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
Treatment Resistent Cancers
Extracorporeal Removal of Drugs: Continuous Renal Replacement Therapy
Treatment Resistant Cancers
Continuous Renal Replacement Therapy

